Laurent Fischer, M.D. is Adverum’s president and chief executive officer and serves as a director. Dr. Fischer has more than 20 years of drug development and commercialization experience in the biopharmaceutical industry. Before joining Adverum, Dr. Fischer was senior vice president and head of the Liver Therapeutic Area at Allergan, PLC. Previously, he served as chairman and chief executive officer of Tobira Therapeutics until its acquisition by Allergan in November 2016. Previously, he served as chairman and chief executive officer of Jennerex, Inc. until its acquisition by SillaJen Biotherapeutics, Inc. Prior to Jennerex, he was co-founder, president and chief executive officer of Ocera Therapeutics and president and chief executive officer of Auxeris Therapeutics, Inc. Over the span of his career, Dr. Fischer has held roles of increasing responsibility at several companies, including, RXCentric, Inc. (now part of Allscripts Healthcare Solutions, Inc.), MedVantx Inc., Dupont Pharmaceuticals, Dupont-Merck, and F. Hoffmann-La Roche.
Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland.
Dr. Fischer currently serves as chairman of the board of CTI Biopharma, as director at Mirum Pharmaceuticals, Inc. and Lycia Therapeutics, and as senior advisor on the Life Sciences Team at Frazier Healthcare Partners.
What is Laurent Fischer's net worth?
The estimated net worth of Laurent Fischer is at least $496,541.95 as of March 15th, 2023. Dr. Fischer owns 692,141 shares of Adverum Biotechnologies stock worth more than $496,542 as of March 31st. This net worth approximation does not reflect any other investments that Dr. Fischer may own. Learn More about Laurent Fischer's net worth.
How do I contact Laurent Fischer?
Has Laurent Fischer been buying or selling shares of Adverum Biotechnologies?
During the past quarter, Laurent Fischer has sold $32,166.42 in Adverum Biotechnologies stock. Most recently, Laurent Fischer sold 41,239 shares of the business's stock in a transaction on Wednesday, March 15th. The shares were sold at an average price of $0.78, for a transaction totalling $32,166.42. Following the completion of the sale, the chief executive officer now directly owns 692,141 shares of the company's stock, valued at $539,869.98. Learn More on Laurent Fischer's trading history.
Who are Adverum Biotechnologies' active insiders?
Are insiders buying or selling shares of Adverum Biotechnologies?
During the last year, Adverum Biotechnologies insiders bought shares 6 times. They purchased a total of 116,925 shares worth more than $111,944.50. During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 107,252 shares worth more than $96,809.22. The most recent insider tranaction occured on March, 15th when insider Brigit Riley sold 7,299 shares worth more than $5,693.22. Insiders at Adverum Biotechnologies own 3.3% of the company.
Learn More about insider trades at Adverum Biotechnologies. Information on this page was last updated on 3/15/2023.
